HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
HeartBeam BEAT recently secured FDA 510(k) clearance for its first-of-its-kind, cable-free synthesized 12-lead ECG technology, marking a major inflection point in the company’s mission to modernize ...
Marks HeartBeam’s transition to commercial company Rapidly growing practice and highly engaged member population to enable broad adoption Enables efficient scaling of additional preventive cardiology ...
HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions, was featured in a recent article that discussed its recognition as a Global IP and Technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results